Related Experiment Video
Updated: Jun 30, 2025
10:16
Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015
13.3K
[BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts]
Jing Pei1, Lin Zhang, Yun-Xiang Jia
1Affiliated Stomatological Hospital of Nanchang University; Key Laboratory of Oral Biomedicine, Jiangxi Province; Jiangxi Province Clinical Research Center for Oral Diseases. Nanchang 330006, Jiangxi Province, China.
Shanghai Kou Qiang Yi Xue = Shanghai Journal of Stomatology
|March 18, 2024
Summary
The BRAF V600E mutation is frequently found in ameloblastomas but not typically in cysts or carcinomas. Immunohistochemistry can help screen for this mutation, aiding in differential diagnosis.
Area of Science:
- Oncology
- Genetics
- Pathology
Context:
- Ameloblastomas are odontogenic tumors with a high recurrence rate.
- Malignant transformation of ameloblastomas into ameloblastic carcinomas is a concern.
- BRAF V600E mutations are implicated in various cancers.
Purpose:
- To investigate the protein and genetic status of BRAF V600E in ameloblastomas, ameloblastic carcinomas, and cysts.
- To determine if BRAF V600E status correlates with ameloblastoma recurrence or malignant transformation.
Summary:
- Immunohistochemistry and quantitative real-time PCR (qPCR) were used to analyze BRAF V600E in 20 cysts, 25 primary ameloblastomas, 25 recurrent ameloblastomas, and 8 ameloblastic carcinomas.
- No correlation was found between BRAF V600E expression and ameloblastoma recurrence.
- BRAF V600E mutations were less frequent in cysts and carcinomas compared to ameloblastomas, with concordance between protein expression and mutation.
Impact:
- BRAF V600E mutation status may aid in differentiating ameloblastomas from cysts and ameloblastic carcinomas.
- Immunohistochemistry serves as a potentially valuable screening method for BRAF V600E mutations in ameloblastoma cases.
